Matinas BioPharma Holdings announced on Friday that it received a non-compliance notice from NYSE American for falling below the exchange's stockholders' equity requirement. The company reported $1.8 million in stockholders' equity as of June 30, below the required $2.0 million, and has posted losses in each of the past five fiscal years. NYSE American has granted the company until October 2, 2027, to regain compliance under its existing plan. The notice does not immediately affect the stock's listing or operations, but failure to regain compliance could lead to delisting proceedings.
Matinas BioPharma Holdings IncCompany fell below NYSE American's stockholders' equity requirement and faces potential delisting if not compliant by 2027.
